In parallel to our HC data, miR-92a inhibitor treatment in Th17-polarized MS patients’ CD4+ T cells also resulted in reduced expression of RORC (Figure 7M), IL-1R, and IL-23R (Supplemental Figure 10, C and D). This evidence concerns the gene RORC and myeloid sarcoma.